Clinical intervention aimed at mitigating the age-related decline in the somatotropic axis, characterized by reduced production and secretion of growth hormone (GH) and Insulin-like Growth Factor 1 (IGF-1). Correction seeks to restore youthful anabolic signaling, improving body composition, bone density, and recovery kinetics. This addresses the endocrine component of aging.
Origin
“Somatopause” is a portmanteau describing the onset of diminished somatotropic (GH-related) function with advancing age. “Correction” refers to the therapeutic strategies employed to normalize this decline, often utilizing secretagogues or replacement therapy.
Mechanism
Correction strategies primarily work by stimulating the pituitary gland to increase pulsatile GH release, either directly or via GHRH analogs, or by supplementing IGF-1 directly. Increased GH levels subsequently enhance lipolysis and promote protein synthesis through the liver’s production of IGF-1. The overall mechanism is to re-engage anabolic signaling pathways that support lean mass maintenance and cellular repair, counteracting sarcopenia.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.